Thieme: Pharmakologie Und Toxikologie

Total Page:16

File Type:pdf, Size:1020Kb

Thieme: Pharmakologie Und Toxikologie 627 Sachverzeichnis Vorbemerkung: Im Text des Buches sind für Wirkstoffe immer die internationalen Freinamen benutzt. Im Register sind die Handels- namen mit ௡ gekennzeichnet. Die Handelsnamen sind in den Tabellen „Notwendige Wirkstoffe“ aufgelistet. A Acetyldigoxin 149 Adenosin 139, 163 – Struktur 145 – als Antiarrhythmikum 162 Abacavir 532, 534 Acetylierer, langsamer 59 – Schmerzempfindung 289 Abarelix 399f Acetylsalicylsäure 310, 314ff – Struktur 139 Abatacept 331 – bei akutem rheumatischen Fieber 324 Adenosindesaminase 462 – bei rheumatoider Arthritis 322 – bei Angina pectoris 182 Adenosindiphosphat 139 ABC-Transporter 30 – Anwendung 314 Adenosinmonophosphat, zyklisches 99f Abciximab 183, 209 – bei Herzinfarkt 184 Adenosin-Nukleotid 139 – Thrombozytenaggregationshemmung – Kontraindikation 316 Adenosin-Rezeptor 139 207 – Metabolismus 315 Adenosintriphosphat 139 Abführmittel-Colon 246 – bei Migräne 307 – Schmerzempfindung 289 Abhängigkeit 49 – Nebenwirkung 315 – als Überträgersubstanz 139 – Hypnotika 363 – Pharmakokinetik 314f Adenylatcyclase 8, 100 Abilify௡ 346 – Re-Infarkt-Prophylaxe 184 Adermin 271 Absence – bei Schlaganfall 186 Adevofir-dipivoxil bei Hepatitis B 253 – Antiepileptikawahl 375 – Schmerztherapie, Stufenschema 305 ADH (antidiuretisches Hormon) s. Adiu- – pyknoleptische, Antiepileptikawahl – Schwangerschaft 316 retin 375 – Struktur 315 Adhäsionsprotein 333 Absorption s. Resorption – Thromboseprophylaxe 209 ADHS (Aufmerksamkeits-Defizit/Hyper- Abstillen 404 – Thrombosetherapie 209 aktivitäts-Syndrom) 362 Acamprosat bei Alkoholentzug 575 – als Thrombozytenaggregationshemm- Adiuretin (s. auch Vasopressin) 232ff, Acarbose 445f stoff 207f 404f Accupro௡ 138 – bei Vorhofflimmern 163 – Nierenfunktion 223 ACE (Angiotensin-Conversions-Enzym) – Wirkungsweise 314 – als peptidischer Botenstoff 133 133 ff Acetylsalicylsäure-Vergiftung 316 – Struktur 404 ACE-Hemmstoff 134ff Aciclovir 527ff Adiuretin-Rezeptor 233 – bei chronischer Herzmuskelinsuffi- – Aktivierung 530 Adonisröschen 149 zienz 152f – Anreicherung 530 Adrekar௡ 163 – Hypertonie-Therapie 173ff, 176 – Blockade der Virus-Vermehrung 528 Adrenalin 83f, 94ff, 105, 184, 188 – bei Raynaud-Syndrom 186 – Struktur 530 – Abbau 96f – Re-Infarkt-Prophylaxe 184 – Wirkung 530 – Abbauprodukte 96 Acebutolol 114 Acidum – Adrenozeptor-Subtypselektivität 99 Acemetacin 317 – citricum bei Hypoazidität 245 – bei akutem Herzmuskelversagen 151 Acerbon௡ 138 – hydrochloricum bei Hypoazidität 245 – Anwendung 94, 102f Acetaminophen s. Paracetamol Acitretin 270 – Freisetzung 95 Acetazolamid 226 – bei Psoriasis 391 – – aus Dipivefrin 102 – Struktur 226 – Struktur 270 – funktionelle Bedeutung 100ff Aceton, Lösungsmittel-Schnüffeln 567 Aclasta௡ 288 – Herzwirkung 150 Acetylcholin 83ff Acne vulgaris, Therapie 392 – Kontraindikation 103 – extraneuronales 84 Acneoxid௡ 393 – Struktur 96, 105 – Freisetzung 85 ACNU௡ 472 – Synthese 95 – intrinsische Aktivität 17 Acridin-Derivate 544f – Wirkmechanismus 94, 99 – Magensäureproduktion 242 Acrod 217 – Wirkung 105 – neuromuskuläre Synapse 276 Acrodermatitis enteropathica 565 – Zusatz zu Lokalanästhetika 291 – Pharmakokinetik 87 Acrylacetat, Lösungsmittel-Schnüffeln Adrenozeptor(en) s. auch α–Rezeptor; s. – Rezeptortypen 85 567 auch -Rezeptor – Struktur 85, 87 ACTH (Corticotropin) 397f – Agonist 99 – Synthese 85 Actinomycine 459 – – Subtypselektivität 99 – Wirkstärke 17 Actonel௡ 288 – Antagonist 99 – Wirkungsweise 87 Actos௡ 450 – – Subtypselektivität 99 Acetylcholinesterase 276f, 548 Acylaminopenicilline 484 – Subtypen 95, 97f – motorische Endplatte 277 Adalat௡ 167, 176 – – Funktion 98 – Reaktivatoren 548 Adalimumab bei rheumatoider Arthritis – – Signalweg 97f Acetylcholinesterase-Hemmer bei Mor- 322 Adriamycin 459 bus Alzheimer 367 Adapalen 270, 392 – Struktur 459 Acetylcholin-Rezeptor, nicotinischer 277 Adefovir 533 Adriblastin௡ 473 Acetylcholin-System 276 – bei Hepatitis B 539 Adsorbens bei akuter Vergiftung 555 Acetylcystein (s. auch N-Acetylcystein) – Struktur 539 Adumbran௡ 360 188 f Adenin, Struktur 461 Advagraf௡ 336 aus: Lüllmann u.a., Pharmakologie und Toxikologie (ISBN 9783133685177) ᮊ 2010 Georg Thieme Verlag KG 628 Sachverzeichnis Advantan௡ 390 Algasidase, Orphan drug 46 Altersdiabetes s. Diabetes mellitus, Typ Aerius௡ 128 Algedrat 244 II Aeromax௡ 107, 192 f Alglucosidase 266 Alt-Insulin 442 Affinität 12ff, 21 Alimta௡ 473 Aludrox௡ 244 Aflatoxine als Karzinogene 594 Aliskiren 134 Aluminium als Gift 564 Agalsidase 266f – Struktur 134 – Antidot 555 Agar-Agar als Laxans 247 Alitretinoin 270 Aluminiumhydroxid 241 Aggrastat௡ 209 Alizaprid als Antiemetikum 372 Aluminiumphosphat 244 Agiolax௡ 250 Alkeran௡ 472 Aluminiumsilikat bei Diarrhö 249 Aglucon 145 Alkohol s. auch Ethanol Alupent௡ 107 Agmatin 115 Alkoholabusus, chronischer Alveofact௡ 194 Agomelatin 352 – Folgen 573f Alvesco௡ 192, 422 – Struktur 352 – Therapie 575 Alzheimer, Morbus 367 Agonist 12ff Alkohol-Dehydrogenase – Therapie 367 – inverser 13 – bei Ethylenglykol-Vergiftung 568 Amalgamfüllung 562 – partieller 12 – Hemmung bei Methanol-Vergiftung Amanita phalloides 587 Agranulozytose 576 α-Amanitin 587 – allergische Reaktion 48 Alkohole als Desinfektionsmittel 542 Amantadin 537 – arzneimittelbedingte 49 Alkoholentzug, Clonidin 115 – Blockade der Virus-Vermehrung 528 Ah-Rezeptor (Arylhydrocarbon-Rezep- Alkoholismus – bei Morbus Parkinson 369 tor) 570 – Folgen 573f Amaryl௡ 451 Ähnlichkeitsregel, Homöopathie 74 – Therapie 575 Amatoxin 587 AIDS, antivirale Substanzen 532ff Alkohol-Syndrom, embryofetales 574 Ambrisentan 168 Airol௡ 393 Alkohol-Vergiftung, Antidot 555 – bei COPD mit pulmonaler Hypertonie Ajmalin 159 Alkylanzien 456ff, 472 193 Akathisie 342 – als Karzinogen 593 – Orphan drug 46 Akineton௡ 370, 555 Alkylierung von Nukleinsäure-Unterein- – bei pulmonaler Hypertonie 194 Aknefug௡ 274 heiten 457 Ambroxol 188f Akromegalie 402 Allergische Reaktion 47f Amfepramon 263 Aktionspotenzial, Herzmuskelzelle 154f – Lokalanästhetika-bedingte 292 Amidotrizoat 590 Aktivin௡ 545 Allergodil௡ 128 – Struktur 590 Aktivität, intrinsische 12ff, 17 Allethrin I 547 Amidotrizoesäure 591 Albendazol 519 – Struktur 547 Amikacin 501 – bei Filariasis 517 Allopurinol 264 – Struktur 501 Albuminlösung 215 – Struktur 264 Amilorid 230 Alcuronium 281 Alloxan 441 – bei chronischer Herzmuskelinsuffi- – Dosis-Wirkungs-Kurve 18 all-trans-Retinal 268f zienz 152 Aldactone௡ 232 – Struktur 269 – Hypertonie-Therapie 173ff Aldara௡ 336 all-trans-Retinoinsäure 268f Amin Aldehyddehydrogenase, Histamin- – pharmakodynamische Anwendung – aromatisches, als Karzinogen 593 Abbau 124 269f – biogenes 123ff Aldehyde als Desinfektionsmittel 542 – Struktur 269 – Ladungszustand 29 Aldesleukin 335 all-trans-Retinol, Struktur 269 – quartäres 29 – antineoplastische Therapie 469 all-trans-Retinsäure 268 – tertiäres 29 Aldosteron 422f Allylamine 521, 525 p-Aminobenzoesäure – Aldehyd-Form, Struktur 423 Almogran௡ 132, 308 – als Lichtschutzmittel 390 – Hemiacetal-Form, Struktur 423 Almotriptan 131f – Struktur 490 – relative Wirkungsstärke 417 – bei Migräne 308 γ-Aminobuttersäure s. GABA – Renin-Angiotensin-System 135 Alna௡ 110 ε-Aminocapronsäure 205f – Struktur 231, 415 Aloe 246 – Struktur 206 – Wirkung, extrarenale 423 Alomide௡ 126 7-Aminocephalosporansäure 484 Aldosteron-Antagonisten 225, 231f, 423 Alosetron bei Colon irritabile 252 – Struktur 484 – bei chronischer Herzmuskelinsuffi- Alphagan௡ 121 Aminogluthetimid 432 zienz 153 Alpharezeptorenblocker s. α-Blocker – Struktur 432 Aldrin 546 Alprazolam Aminoglykoside 495, 500ff – Struktur 546 – Arzneimittel-Interferenz 56 – Anwendung 501 Aldurazyme௡ 266 – Cytochrom-P450-Isoform 56 – Fruchtschädigung 52 Alemtuzumab 467f – Struktur 355 – Hemmung der bakteriellen Protein- Alendronat 286 Alprenolol, Anreicherung in Herzmus- synthese 496 Alendronsäure, Struktur 285 kelzellen 27 – Kontraindikation 501 Alexan௡ 473 Alraune 459 – Nebenwirkungen 500 Alfacalcidol bei Osteoporose 284 Altargo௡ 504 – Ototoxizität 501 Alfacid௡ 508 Alteplase 204ff – Pharmakokinetik 500 Alfason௡ 391 – Fibrinolyse-Übersicht 204 – Wirkungsweise 500 Alfentanil 302 – bei Herzinfarkt 184 – zellulärer Wirkort 476 Alfunar௡ 110 – bei Schlaganfall 186 6-Aminopenicillansäure 479 Alfuzosin 110, 118 Alter Mensch, Arzneimitteldosierung 61 – Struktur 479 aus: Lüllmann u.a., Pharmakologie und Toxikologie (ISBN 9783133685177) ᮊ 2010 Georg Thieme Verlag KG Sachverzeichnis 629 Aminopenicilline 482f – Orphan drug 46 – Stickstoffmonoxid-Wirkung 179 Aminophenazon 309 – Struktur 470 Angionorm௡ 132 5-Aminosalicylsäure bei chronisch-ent- Anakinra 326, 330 Angioödem, hereditäres 135 zündlicher Darmerkrankung 251 – bei rheumatoider Arthritis 322 Angiopathie, diabetische 443 p-Aminosalicylsäure gegen Tuberkulose Analeptika s. Psychoanaleptika Angiotensin als peptidischer Botenstoff 508 Analgesie 289ff 133 Aminosäuren als Überträgersubstanz – Grundprinzipien 289 Angiotensin I 133ff 139 f Analgetika 305ff Angiotensin II 133ff Amintransporthemmung, Cocain- – antipyretische 308ff – Kinetik 36 bedingte 108 – Schwangerschaft 307 – Nierenfunktion 223 Amiodaron 159f, 163 Analgetika-Abusus 318 Angiotensin-Conversions-Enzym s. ACE – Neuropathie 306 Analgetika-Nephropathie 318 Angiotensinogen 133ff – Phospholipidose 36 Analgetikum-Asthma 315 Angiotensin-II-Rezeptor, AT1-Subtyp 134 – Struktur 159 Analog-Präparat VII, 15 Angiotensin-II-Rezeptor-Antagonisten – bei Vorhofflimmern 163 Analogsubstanz 65 134, 137 f Amisulprid 345 Anämie – Hypertonie-Therapie 173f Amitriptylin 347, 349f – aplastische 214 – bei Raynaud-Syndrom 186 – Arzneimittel-Interferenz 56 – arzneimittelbedingte 49 Angiox௡
Recommended publications
  • Minnesota Statutes 1979 Supplement
    MINNESOTA STATUTES 1979 SUPPLEMENT 152.01 PROHIBITED DRUGS CHAPTER 152. PROHIBITED DRUGS Sec. 152.01 Definitions. 152.02 Schedules of controlled substances; admin­ istration of chapter. 152.01 Definitions. [For text of subds 1 to 8, see M.S.1978] Subd. 9. Marijuana. "Marijuana" means all parts of the plant of any species of the genus Cannabis, including all agronomical varieties, whether growing or not; the seeds thereof; the resin extracted from any part of such plant; and every compound, manufacture, salt, derivative, mixture, or preparation of such plant, its seeds or resin, but shall not include the mature stalks of such plant, fiber from such stalks, oil or cake made from the seeds of such plant, any other compound, manufacture, salt, derivative, mix­ ture, or preparation of such mature stalks, except the resin extracted therefrom, fiber, oil, or cake, or the sterilized seed of such plant which is incapable of germination. [For text of subds 10 to 17, see M.S.1978] [ 1979 c 157 s 1 ] 152.02 Schedules of controlled substances; administration of chapter. [For text of subd 1, see M.S.1978) Subd. 2. The following items are listed in Schedule I: (1) Any of the following substances, including their isomers, esters, ethers, salts, and salts of isomers, esters, and ethers, unless specifically excepted, whenever the exis­ tence of such isomers, esters, ethers and salts is possible within the specific chemical des­ ignation: Acetylmethadol; Allylprodine; Alphacetylmethadol; Alphameprodine; Alpham- ethadol; Benzethidine; Betacetylmethadol; Betameprodine; Betamethadol; Betaprodine; Clonitazene; Dextromoramide; Dextrorphan; Diampromide; Diethyliambutene; Dime- noxadol; Dimepheptanol; Dimethyliambutene; Dioxaphetyl butyrate; Dipipanone; Ethylmethylthiambutene; Etonitazene; Etoxeridine; Furethidine; Hydroxypethidine; Ke- tobemidone; Levomoramide; Levophenacylmorphan; Morpheridine; Noracymethadol; Norlevorphanol; Normethadone; Norpipanone; Phenadoxone; Phenampromide; Pheno- morphan; Phenoperidine; Piritramide; Proheptazine; Properidine; Racemoramide; Tri­ meperidine.
    [Show full text]
  • Federal Register/Vol. 84, No. 26/Thursday, February 7, 2019/Notices
    2570 Federal Register / Vol. 84, No. 26 / Thursday, February 7, 2019 / Notices National Fire Protection Association Register pursuant to Section 6(b) of the Morrissette Drive, Springfield, Virginia (‘‘NFPA’’) has filed written notifications Act on October 22, 2018 (83 FR 53297). 22152. simultaneously with the Attorney Suzanne Morris, SUPPLEMENTARY INFORMATION: General and the Federal Trade The Commission disclosing additions or Chief, Premerger and Division Statistics Unit, Attorney General has delegated his changes to its standards development Antitrust Division. authority under the Controlled activities. The notifications were filed [FR Doc. 2019–01489 Filed 2–6–19; 8:45 am] Substances Act to the Administrator of for the purpose of extending the Act’s BILLING CODE 4410–11–P the Drug Enforcement Administration provisions limiting the recovery of (DEA), 28 CFR 0.100(b). Authority to antitrust plaintiffs to actual damages exercise all necessary functions with under specified circumstances. DEPARTMENT OF JUSTICE respect to the promulgation and implementation of 21 CFR part 1301, Specifically, NFPA has provided an Drug Enforcement Administration updated and current list of its standards incident to the registration of development activities, related technical [Docket No. DEA–392] manufacturers, distributors, dispensers, committee and conformity assessment importers, and exporters of controlled activities. Information concerning NFPA Bulk Manufacturer of Controlled substances (other than final orders in regulations, technical committees,
    [Show full text]
  • Chapter 329 [New] Uniform Controlled Substances Act
    CHAPTER 329 [NEW] UNIFORM CONTROLLED SUBSTANCES ACT Part I. General Provisions Section 329-1 Definitions 329-2 Hawaii advisory commission on drug abuse and controlled substances; number; appointment 329-3 Annual report 329-4 Duties of the commission Part II. Standards and Schedules 329-11 Authority to schedule controlled substances 329-12 Nomenclature 329-13 Schedule I tests 329-14 Schedule I 329-15 Schedule II tests 329-16 Schedule II 329-17 Schedule III Tests 329-18 Schedule III 329-19 Schedule IV tests 329-20 Schedule IV 329-21 Schedule V tests 329-22 Schedule V 329-23 Republishing and distribution of schedules Part III. Regulation of Manufacture, Distribution, Prescription, and Dispensing of Controlled Substances 329-31 Rules 329-31.5 Clinics 329-32 Registration requirements 329-33 Registration 329-34 Revocation and suspension of registration 329-35 Order to show cause 329-36 Records of registrants 329-37 Filing requirements 329-38 Prescriptions 329-39 Labels 329-40 Methadone treatment programs Part IV. Offenses and Penalties 329-41 Prohibited acts B-penalties 329-42 Prohibited acts C-penalties 329-43 Penalties under other laws 329-43.5 Prohibited acts related to drug paraphernalia Amended 0612 1 329-44 Notice of conviction to be sent to licensing board, department of commerce and consumer affairs 329-45 Repealed 329-46 Prohibited acts related to visits to more than one practitioner to obtain controlled substance prescriptions 329-49 Administrative penalties 329-50 Injunctive relief Part V. Enforcement and Administrative Provisions 329-51 Powers of enforcement personnel 329-52 Administrative inspections 329-53 Injunctions 329-54 Cooperative arrangements and confidentiality 329-55 Forfeitures 329-56 Burden of proof; liabilities 329-57 Judicial review 329-58 Education and research 329-59 Controlled substance registration revolving fund; established Part VI.
    [Show full text]
  • Supplement 1: Additional Tables and Figures
    BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance Supplemental material placed on this supplemental material which has been supplied by the author(s) BMJ Global Health Supplement 1: Additional tables and figures Box S1: Substances included and excluded from the International Narcotic Control Board (INCB) data on narcotic consumption, in alphabetical order. Opioids included in the opioid consumption calculation: 1. (+)-cis-3-methylfental 35. Bezitramide 2. 3-Acetylmorphine 36. Butyrfentanyl 3. 3-Methylfentanyl 37. Carfentanil 4. 3-Methylthiofentanyl 38. Carfentanyl 5. 3-Monoacetylmorphine 39. Clonitazene 6. 4-Fluoroisobutyrfentanyl 40. Codeine 7. 6-Acetylmorphine 41. Codeine-6GLUC 8. 6-Monoacetylmorphine 42. Codeine-6-glucuronide 9. Acetorphine 43. Codeine-Methyl 10. Acetyl-alpha-methylfentanyl 44. Codeine-N-oxide 11. Acetyldihydrocodeine 45. Codoxime 12. Acetylfentanyl 46. Conc. of poppy straw (C) ACA 13. Acetylmethadol 47. Conc. of poppy straw (C) AMA 14. Acetylmorphine 48. Conc. of poppy straw (C) AOA 15. Acrylfentanyl 49. Conc. of poppy straw (C) ATA 16. AH-7921 50. Conc. of poppy straw (C) GW 17. Alfentanil 51. Conc. of poppy straw (M) ACA 18. Allylprodine 52. Conc. of poppy straw (M) AMA 19. Alphacetylmethadol 53. Conc. of poppy straw (M) AOA 20. Alphameprodine 54. Conc. of poppy straw (M) ATA 21. Alphamethadol 55. Conc. of poppy straw (M) GW 22. alpha-Methylfentanyl 56. Conc. of poppy straw (N) GW 23. alpha-Methylthiofentanyl 57. Conc. of poppy straw (O) 24. Alphaprodine 58. Conc. of poppy straw (O) ACA 25. Anileridine 59. Conc. of poppy straw (O) AMA 26. Benzethidine 60. Conc. of poppy straw (O) AOA 27.
    [Show full text]
  • List of Narcotic Drugs Under International Control
    International Narcotics Control Board Yellow List Annex to Forms A, B and C 59th edition, July 2020 LIST OF NARCOTIC DRUGS UNDER INTERNATIONAL CONTROL Prepared by the INTERNATIONAL NARCOTICS CONTROL BOARD* Vienna International Centre P.O. Box 500 A-1400 Vienna, Austria Internet address: http://www.incb.org/ in accordance with the Single Convention on Narcotic Drugs, 1961** Protocol of 25 March 1972 amending the Single Convention on Narcotic Drugs, 1961 * On 2 March 1968, this organ took over the functions of the Permanent Central Narcotics Board and the Drug Supervisory Body, r etaining the same secretariat and offices. ** Subsequently referred to as “1961 Convention”. V.20-03697 (E) *2003697* Purpose The Yellow List contains the current list of narcotic drugs under international control and additional relevant information. It has been prepared by the International Narcotics Control Board to assist Governments in completing the annual statistical reports on narcotic drugs (Form C), the quarterly statistics of imports and exports of narcotic drugs (Form A) and the estimates of annual requirements for narcotic drugs (Form B) as well as related questionnaires. The Yellow List is divided into four parts: Part 1 provides a list of narcotic drugs under international control in the form of tables and is subdivided into three sections: (1) the first section includes the narcotic drugs listed in Schedule I of the 1961 Convention as well as intermediate opiate raw materials; (2) the second section includes the narcotic drugs listed in Schedule II of the 1961 Convention; and (3) the third section includes the narcotic drugs listed in Schedule IV of the 1961 Convention.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2014/0144429 A1 Wensley Et Al
    US 2014O144429A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2014/0144429 A1 Wensley et al. (43) Pub. Date: May 29, 2014 (54) METHODS AND DEVICES FOR COMPOUND (60) Provisional application No. 61/887,045, filed on Oct. DELIVERY 4, 2013, provisional application No. 61/831,992, filed on Jun. 6, 2013, provisional application No. 61/794, (71) Applicant: E-NICOTINE TECHNOLOGY, INC., 601, filed on Mar. 15, 2013, provisional application Draper, UT (US) No. 61/730,738, filed on Nov. 28, 2012. (72) Inventors: Martin Wensley, Los Gatos, CA (US); Publication Classification Michael Hufford, Chapel Hill, NC (US); Jeffrey Williams, Draper, UT (51) Int. Cl. (US); Peter Lloyd, Walnut Creek, CA A6M II/04 (2006.01) (US) (52) U.S. Cl. CPC ................................... A6M II/04 (2013.O1 (73) Assignee: E-NICOTINE TECHNOLOGY, INC., ( ) Draper, UT (US) USPC ..................................................... 128/200.14 (21) Appl. No.: 14/168,338 (57) ABSTRACT 1-1. Provided herein are methods, devices, systems, and computer (22) Filed: Jan. 30, 2014 readable medium for delivering one or more compounds to a O O Subject. Also described herein are methods, devices, systems, Related U.S. Application Data and computer readable medium for transitioning a Smoker to (63) Continuation of application No. PCT/US 13/72426, an electronic nicotine delivery device and for Smoking or filed on Nov. 27, 2013. nicotine cessation. Patent Application Publication May 29, 2014 Sheet 1 of 26 US 2014/O144429 A1 FIG. 2A 204 -1 2O6 Patent Application Publication May 29, 2014 Sheet 2 of 26 US 2014/O144429 A1 Area liquid is vaporized Electrical Connection Agent O s 2.
    [Show full text]
  • Tennessee Drug Statutes (Listed in Numerical Order)
    Tennessee Drug Statutes (listed in numerical order) 39-17-405. Criteria for Schedule I. • The commissioner of mental health and substance abuse services, upon the agreement of the commissioner of health, shall place a substance in Schedule I upon finding that the substance has: o (1) High potential for abuse; and o (2) No accepted medical use in treatment in the United States or lacks accepted safety for use in treatment under medical supervision. 39-17-406. Controlled substances in Schedule I. • (a) Schedule I consists of the drugs and other substances, by whatever official name, common or usual name, chemical name, or brand name designated, listed in this section. • (b) Opiates, unless specifically excepted or unless listed in another schedule, means any of the following opiates, including their isomers, esters, ethers, salts and salts of isomers, esters, and ethers, whenever the existence of such isomers, esters, ethers, and salts is possible within the specific chemical designation. For the purposes of subdivision (b)(34) only, the term isomer includes the optical and geometric isomers. o (1) Acetyl-alpha-methylfentanyl (N-[1-(1-methyl-2-phenethyl)-4- piperidinyl]-N-phenylacetamide); o (2) Acetylmethadol; o (3) Allylprodine; o (4) Alphacetylmethadol (except levo-alphacetylmethadol also known as levo-alpha-acetylmethadol; levomethadyl acetate; or LAAM); o (5) Alphameprodine; o (6) Alphamethadol; o (7) Alpha-methylfentanyl (N-[1-(alpha-methyl-beta-phenyl)ethyl-4- piperidyl]propionanilide; 1-(1-methyl-2-phenylethyl)-4-(N- propanilido)piperidine;
    [Show full text]
  • Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DIX to the HTSUS—Continued
    20558 Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DEPARMENT OF THE TREASURY Services, U.S. Customs Service, 1301 TABLE 1.ÐPHARMACEUTICAL APPEN- Constitution Avenue NW, Washington, DIX TO THE HTSUSÐContinued Customs Service D.C. 20229 at (202) 927±1060. CAS No. Pharmaceutical [T.D. 95±33] Dated: April 14, 1995. 52±78±8 ..................... NORETHANDROLONE. A. W. Tennant, 52±86±8 ..................... HALOPERIDOL. Pharmaceutical Tables 1 and 3 of the Director, Office of Laboratories and Scientific 52±88±0 ..................... ATROPINE METHONITRATE. HTSUS 52±90±4 ..................... CYSTEINE. Services. 53±03±2 ..................... PREDNISONE. 53±06±5 ..................... CORTISONE. AGENCY: Customs Service, Department TABLE 1.ÐPHARMACEUTICAL 53±10±1 ..................... HYDROXYDIONE SODIUM SUCCI- of the Treasury. NATE. APPENDIX TO THE HTSUS 53±16±7 ..................... ESTRONE. ACTION: Listing of the products found in 53±18±9 ..................... BIETASERPINE. Table 1 and Table 3 of the CAS No. Pharmaceutical 53±19±0 ..................... MITOTANE. 53±31±6 ..................... MEDIBAZINE. Pharmaceutical Appendix to the N/A ............................. ACTAGARDIN. 53±33±8 ..................... PARAMETHASONE. Harmonized Tariff Schedule of the N/A ............................. ARDACIN. 53±34±9 ..................... FLUPREDNISOLONE. N/A ............................. BICIROMAB. 53±39±4 ..................... OXANDROLONE. United States of America in Chemical N/A ............................. CELUCLORAL. 53±43±0
    [Show full text]
  • WO 2014/085719 Al 5 June 2014 (05.06.2014) P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2014/085719 Al 5 June 2014 (05.06.2014) P O P C T (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every A61M 15/00 (2006.01) A24F 47/00 (2006.01) kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, (21) International Application Number: BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, PCT/US20 13/072426 DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, (22) International Filing Date: HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, 27 November 2013 (27.1 1.2013) KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, (25) Filing Language: English OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, (26) Publication Language: English SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, (30) Priority Data: ZW. 61/730,738 28 November 2012 (28. 11.2012) US 61/794,601 15 March 2013 (15.03.2013) US (84) Designated States (unless otherwise indicated, for every 61/83 1,992 6 June 2013 (06.06.2013) us kind of regional protection available): ARIPO (BW, GH, 61/887,045 4 October 201 3 (04.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 8,158,152 B2 Palepu (45) Date of Patent: Apr
    US008158152B2 (12) United States Patent (10) Patent No.: US 8,158,152 B2 Palepu (45) Date of Patent: Apr. 17, 2012 (54) LYOPHILIZATION PROCESS AND 6,884,422 B1 4/2005 Liu et al. PRODUCTS OBTANED THEREBY 6,900, 184 B2 5/2005 Cohen et al. 2002fOO 10357 A1 1/2002 Stogniew etal. 2002/009 1270 A1 7, 2002 Wu et al. (75) Inventor: Nageswara R. Palepu. Mill Creek, WA 2002/0143038 A1 10/2002 Bandyopadhyay et al. (US) 2002fO155097 A1 10, 2002 Te 2003, OO68416 A1 4/2003 Burgess et al. 2003/0077321 A1 4/2003 Kiel et al. (73) Assignee: SciDose LLC, Amherst, MA (US) 2003, OO82236 A1 5/2003 Mathiowitz et al. 2003/0096378 A1 5/2003 Qiu et al. (*) Notice: Subject to any disclaimer, the term of this 2003/OO96797 A1 5/2003 Stogniew et al. patent is extended or adjusted under 35 2003.01.1331.6 A1 6/2003 Kaisheva et al. U.S.C. 154(b) by 1560 days. 2003. O191157 A1 10, 2003 Doen 2003/0202978 A1 10, 2003 Maa et al. 2003/0211042 A1 11/2003 Evans (21) Appl. No.: 11/282,507 2003/0229027 A1 12/2003 Eissens et al. 2004.0005351 A1 1/2004 Kwon (22) Filed: Nov. 18, 2005 2004/0042971 A1 3/2004 Truong-Le et al. 2004/0042972 A1 3/2004 Truong-Le et al. (65) Prior Publication Data 2004.0043042 A1 3/2004 Johnson et al. 2004/OO57927 A1 3/2004 Warne et al. US 2007/O116729 A1 May 24, 2007 2004, OO63792 A1 4/2004 Khera et al.
    [Show full text]
  • Wo 2008/127291 A2
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date PCT (10) International Publication Number 23 October 2008 (23.10.2008) WO 2008/127291 A2 (51) International Patent Classification: Jeffrey, J. [US/US]; 106 Glenview Drive, Los Alamos, GOlN 33/53 (2006.01) GOlN 33/68 (2006.01) NM 87544 (US). HARRIS, Michael, N. [US/US]; 295 GOlN 21/76 (2006.01) GOlN 23/223 (2006.01) Kilby Avenue, Los Alamos, NM 87544 (US). BURRELL, Anthony, K. [NZ/US]; 2431 Canyon Glen, Los Alamos, (21) International Application Number: NM 87544 (US). PCT/US2007/021888 (74) Agents: COTTRELL, Bruce, H. et al.; Los Alamos (22) International Filing Date: 10 October 2007 (10.10.2007) National Laboratory, LGTP, MS A187, Los Alamos, NM 87545 (US). (25) Filing Language: English (81) Designated States (unless otherwise indicated, for every (26) Publication Language: English kind of national protection available): AE, AG, AL, AM, AT,AU, AZ, BA, BB, BG, BH, BR, BW, BY,BZ, CA, CH, (30) Priority Data: CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, 60/850,594 10 October 2006 (10.10.2006) US ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, (71) Applicants (for all designated States except US): LOS LR, LS, LT, LU, LY,MA, MD, ME, MG, MK, MN, MW, ALAMOS NATIONAL SECURITY,LLC [US/US]; Los MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, Alamos National Laboratory, Lc/ip, Ms A187, Los Alamos, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, NM 87545 (US).
    [Show full text]
  • Diethyl Azodicarboxylate
    Global Imaging Insights Image ISSN: 2399-7397 Fucitol, pterodactyladiene, DEAD or DEADCAT (DiEthyl AzoDiCArboxylaTe), skatole, the nanoputians, thebacon, pikachurin, tie fighter, spermidine and mirasorvone nano molecules incorporation into the nano polymeric matrix (NPM) by immersion of the nano polymeric modified electrode (NPME) as molecular enzymes and drug targets for human cancer cells, tissues and tumors treatment under synchrotron and synchrocyclotron radiations Alireza Heidari* Faculty of Chemistry, California South University, 14731 Comet St. Irvine, CA 92604, USA In the current editorial, we study Fucitol, Pterodactyladiene, DEAD electropreparation of polymeric Nano film is very important, because or DEADCAT (DiEthyl AzoDiCArboxylaTe), Skatole, the NanoPutians, properties of polymeric Nano films depend on the working electrode Thebacon, Pikachurin, Tie Fighter, Spermidine and Mirasorvone Nano anti–cancer Nano materials. The ease and fast preparation and of molecules (Figure 1) incorporation into the Nano Polymeric Matrix obtaining a new reproducible surface, the low residual current, porous (NPM) by immersion of the Nano Polymeric Modified Electrode surface and low cost of Multi–Walled Carbon Nanotubes (MWCNTs) (NPME) as molecular enzymes and drug targets for human cancer cells, paste are some advantages of Carbon Paste Electrode (CPE) over all tissues and tumors treatment under synchrotron and synchrocyclotron other solid electrodes [28-92]. radiations. In this regard, the development of Chemical Modified Electrodes (CEMs) is at present an area of great interest. CEMs can be On the other hand, it has been shown that, macrocyclic complexes divided broadly into two main categories; namely, surface modified of Fucitol, Pterodactyladiene, DEAD or DEADCAT (DiEthyl and bulk modified electrodes. Methods of surface modification include AzoDiCArboxylaTe), Skatole, the NanoPutians, Thebacon, Pikachurin, adsorption, covalent bonding, attachment of polymer Nano films, Tie Fighter, Spermidine and Mirasorvone Nano molecules are interest etc.
    [Show full text]